DAX20.642 -5,0%ESt504.878 -4,6%Top 10 Crypto11,23 +2,3%Dow38.315 -5,5%Nas15.588 -5,8%Bitcoin76.567 +0,1%Euro1,0961 ±-0,0%Öl66,06 -5,4%Gold3.038 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Tesla A1CX3T Rheinmetall 703000 Apple 865985 Amazon 906866 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 Deutsche Bank 514000 Lufthansa 823212 Volkswagen (VW) vz. 766403 BASF BASF11 Infineon 623100 Microsoft 870747 Allianz 840400 Nike 866993
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Zölle: China schlägt zurück -- DAX geht massiv tiefer ins Wochenende -- Wall Street stürzt letztlich ab -- Aktien von Rheinmetall, RENK & HENSOLDT im Minus -- Novo Nordisk, Apple im Fokus
Top News
Die Highlights im TecDAX: Gewinner und Verlierer der KW 14 im Überblick Die Highlights im TecDAX: Gewinner und Verlierer der KW 14 im Überblick
KW 14: So performten die MDAX-Aktien in der vergangenen Woche KW 14: So performten die MDAX-Aktien in der vergangenen Woche
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Bis zu 3,05 % Zinsen: Jetzt die besten Tagesgeld-Angebote checken

Abbott Laboratories Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
113,40 EUR -6,02 EUR -5,04 %
STU
124,47 USD -7,20 USD -5,47 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.208,27 Mrd. EUR

KGV14,81Div. Rendite1,98%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN850103

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS0028241000

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABT

Abbott Laboratories Aktien News

DatumMeistgelesen
PR NewswireLate-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies
MyDividendsAbbott Laboratories kündigt 395. Quartalsdividende in Folge an
PR NewswireAbbott Declares 395th Consecutive Quarterly Dividend
PR NewswireABT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 31, 2022 in the Class Action Filed on Behalf of Abbott Laboratories Shareholders
PR NewswireCLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Abbott Investors of a Lead Plaintiff Deadline of October 31, 2022
PR NewswireHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm's Attorneys, Infant Formula-Related Securities Fraud Class Action Filed
PR NewswireThree-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery
PR NewswireROSEN, A LEADING LAW FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT
PR NewswireInvestor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Abbott Laboratories (ABT) Investors of Class Action and to Actively Participate
PR NewswireNew Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients
PR NewswireNew Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients
PR NewswireFDA Approves Abbott's New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions
PR NewswireNew Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions
PR NewswireNew Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions
PR NewswireAbbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals
PR NewswireAbbott Introduces Canada's First Remote Neuromodulation Patient-Care Technology, NeuroSphere™ Virtual Clinic, to Treat People with Chronic Pain and Movement Disorders*
PR NewswireAbbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance
PR NewswireAbbott Receives FDA's Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression
PR NewswireAbbott Hosts Conference Call for Second-Quarter Earnings
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
MyDividendsAbbott Laboratories kündigt 394. Quartalsdividende in Folge an
PR NewswireAbbott Declares 394th Consecutive Quarterly Dividend
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
PR NewswireLate-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor
PR NewswireAbbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System
PR NewswireAbbott's FreeStyle Libre® 3 Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
PR NewswireNew Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies
PR NewswireNew Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies
PR NewswireAbbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
PR NewswireAbbott to Release Metabolic Nutrition Formulas
PR NewswireStudy Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott's Ablation Device Remain Symptom-Free for at Least 15 Months
PR NewswireAbbott Strengthens Left Atrial Appendage Closure Leadership With U.S. Availability of Amplatzer™ Steerable Delivery Sheath for the Company's Amulet™ Device
PR NewswireNew Analysis Shows that Abbott's FreeStyle Libre® System Provides Similar and Sustained Reductions in Glucose Levels for People with Both Type 1 and Type 2 Diabetes
PR NewswireAbbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes
PR NewswireAbbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes
PR NewswireAbbott Recommends Rejection of Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
PR NewswireAbbott Strengthens Its Connected Care Technologies with Latest NeuroSphere™ myPath™ Digital Health App
MyDividendsAbbott Laboratories schüttet 393. Quartalsdividende in Folge aus
PR NewswireAbbott Reports First-Quarter 2022 Results
Wer­bung

Abbott Laboratories News

Abbott Laboratories News: auf dieser Seite finden Sie alle Abbott Laboratories News und Nachrichten zur Abbott Laboratories Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Abbott Laboratories News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Abbott Laboratories News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.